HateEraser removes hate-based graffiti in communities and gives first-time offenders a second chance through judge-mandated service NEW YORK, Nov. 16,...
PLEASANTON, Calif., Nov. 16, 2024 /PRNewswire/ -- This Black Friday, DermRays is excited to announce its most significant sale of...
Boston Female Leaders Support Whittier Street Health Center's Vulnerable and Underserved Women and FamiliesBOSTON, MA / ACCESSWIRE / November 16,...
SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic...
MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced...
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the “Company” or “Eagle”)...
BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform...
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing...
– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18th at 7:30 a.m....
Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study...
Hanna Longstaff Founder of Mind Food Body Ltd KENT, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Mind Food Body...
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the...
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy...
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared...
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared...
Phase 2 study results to be presented at The Liver Meeting® 2024 of AASLD BJT-778 900 mg dosed every four weeks...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use...
Both ECC4703 and ECC0509 demonstrated best-in-class potential, with favorable safety and tolerability profiles, clear target engagement and encouraging efficacy signalsBOSTON...